Cerebral Vein Thrombosis, Cerebral Venous Sinus Thrombosis
Conditions
Brief summary
The NoCVT study will investigate CVT (2014-2023) in a large Norwegian population (\> 3 millions) using several approaches combining existing health registries, clinical databases and new prospectively collected clinical data to explore epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of CVT.
Detailed description
A retrospective hospital-based chart review will be conducted at 13 different hospitals covering all four health regions and more than 3 million inhabitants in Norway. These 13 hospitals are Akershus University Hospital, Haukeland University Hospital. Oslo University Hospital (Ullevål), Sørlandet Hospital Kristiansand, Drammen Hospital, St.Olavs Hospital, Nordlandsykehuset Bodø, University Hospital of North Norway, Innlandet Hospital Lillehammer, Tønsberg Hospital, Telemark Hospital (Skien), Molde Hospital and Stavanger University Hospital. A search will be made in the clinical database for patients with the relevant diagnosis of CVT in the period between January 1, 2014, and December 31, 2023. Data from hospital charts will be linked with data from Statistics Norway (SSB), FD-Trygd, and Norwegian Prescription Database (NorPD). Using this combination of clinical data and health registries will make it possible to describe risk factors, clinical and radiological presentation, treatment and short-term outcome in a large Norwegian CVT cohort. Further, data from hospitals will be linked with data from SSB, FD-Trygd, NorPD, Norwegian Patient Registry (NPR) and Cause of Death Registry (DÅR) up to five years after CVT. Using this methodology will make it possible to investigate overall long-term prognosis and outcomes in terms of mortality, health care utilisation, medication use and working situation up to five years after CVT in a large Norwegian cohort. Lastly, a prospective follow-up study will include patients that have been diagnosed with CVT at the NoCVT hospitals during 2019-2023. By combining the collected data from the retrospective hospital chart review with the new follow-up interviews and self-reported questionnaires it will be possible to describe quality of life, vocational outcomes, psychological distress, depression, insomnia and disease-related disability in CVT.
Interventions
None listed
Sponsors
Oslo University Hospital
Haukeland University Hospital
Drammen sykehus
Sorlandet Hospital HF
St. Olavs Hospital
Nordlandssykehuset HF
University Hospital of North Norway
University of Oslo
Rigshospitalet, Denmark
Hospital de Santa Maria, Portugal
Sykehuset Innlandet HF
Molde Hospital
Helse Stavanger HF
Sykehuset Telemark
Sykehuset i Vestfold HF
University Hospital, Akershus
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* A diagnosis of CVT 2014-2023 from the 13 participating primary hospitals
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality of CVT in a Norwegian population | Baseline, 3 months, 12 months, 24 months and 5 years | Number dead vs total number of cases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Nursing home after CVT | Baseline to five years | Number of CVT cases in need for nursing home |
| Use of anti-coagulation in the long-term after CVT | Baseline to five years | Number of cases with CVT using anti-coagulation |
| New diagnosis after CVT | Baseline to five years | Type of new diagnosis among CVT cases |
| Health care utilisation after CVT | Baseline to five years | Number of new health care system contacts among CVT cases |
| Re-admission after CVT | Baseline to five years | Number of new re-admission among CVT cases |
| Use of anti-platelet therapy in the long-term after CVT | Baseline to five years | Number of cases with CVT using anti-platelet therapy |
| Use of painkillers in the long-term after CVT | Baseline to five years | Number of cases with CVT using painkillers |
| Use of headache prophylactics in the long-term after CVT | Baseline to five years | Number of cases with CVT using headache prophylactics |
| Use of anti-epileptic drugs in the long-term after CVT | Baseline to five years | Number of cases with CVT using anti-epileptic drugs |
| New prescriptions after CVT | Baseline to five years | Type of new prescriptions among CVT cases |
| Sick-leave after CVT | Baseline to five years | Number of cases with CVT on sick-leave |
| Disability pension after CVT | Baseline to five years | Number of cases with CVT on disability pension |
| Headache after CVT | Baseline to five years | Type and frequency |
| Headache-related quality of life after CVT | Baseline to five years | Migraine Disability Assessment Score and Headache Impact Test-6 |
| Seizure/epilepsy after CVT | Baseline to five years | Type and frequency |
| Epilepsy-related quality of life after CVT | Baseline to five years | Quality of Life in Epilepsy Inventory-31 |
| Quality of life after CVT | Baseline to five years | EuroQoL 5 |
| Psychological distress after CVT | Baseline to five years | Patient Health Questionnaire-9 and Hospital Anxiety and Depression Scale |
| Sleep problems after CVT | Baseline to five years | Bergen Insomnia Scale |
| Use of anti-depressants in the long-term after CVT | Baseline to five years | Number of cases with CVT using anti-epileptic drugs |
Countries
Norway
Contacts
Primary ContactEspen Saxhaug Kristoffersen, MD, PhD
Outcome results
None listed